Microvolt T-Wave Alternans Testing Improves Cost Effectiveness of ICDs.

BEDFORD, Mass. -- Award Winning Presentation at American College of Cardiology shows that use of MTWA Testing in MADIT II patients can effectively reduce costs

Cambridge Heart, Inc. (OTCBB-CAMH) today reported on a presentation at The American College of Cardiology given by Dr. Paul Chan from the VA Center for Practice Management & Outcomes Research, and the University of Michigan, Ann Arbor, MI. The objective of the study was to evaluate the cost effectiveness of Implantable Cardioverter Defibrillator (ICD) therapy in MADIT II eligible patients with and without risk stratification using Microvolt T-Wave Alternans. Three treatment strategies were evaluated, medical therapy alone, ICDs for all, and the utilization of Microvolt T-Wave Alternans as a risk stratification tool to provide ICDs for non-negative MTWA patients only.

A Markov model was utilized to simulate a range of variables influencing the cost-effectiveness of ICD implantation including the initial cost of ICD implant, cost of MTWA testing, complications, ICD replacements, death rates, etc. The results of the simulations revealed an Incremental Cost Effectiveness Ratio (ICER) of $88,700 per Quality Adjusted Life Year (QALY) in the ICDs FOR ALL strategy as compared to the use of MTWA risk stratification. The use of MTWA in risk stratifying the population resulted in a $48,800 ICER as compared to medical management.

Dr. Paul Chan commenting on the study said, "We performed this analysis because the potential cost implication of ICD therapy is immense with an estimated incremental societal cost of $2.9 billion per year as compared to standard medical therapy, just for MADIT II eligible patients. As 82 % of the potential benefit of the ICDs was achieved by implanting ICDs into the 67% of patients who were MTWA non negative, the data suggests that the use of risk stratification make good sense, potentially saving $700 million per year in the MADIT II population alone."

Commenting for the company, David Chazanovitz, President and CEO of Cambridge Heart said, "We applaud Dr. Chan's efforts. The results of this study validate the common sense approach which suggests that placing expensive, life saving therapy is much more cost effective when you risk stratify the population into patients who are unlikely to benefit from the ICD from those who will benefit most from the therapy. We also congratulate Dr. Chan with the announcement at the end of the day that his study won first place in the ACC's prestigious Young Investigators Awards Competition."

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or, who are at risk of, life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.

Statements contained in this press release about anticipated revenue growth, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include customer delays in making final buying decisions, decreased demand for our products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.